Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Ir-Vax by ImmunoRestoration for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Ir-Vax is under clinical development by ImmunoRestoration and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to GlobalData,...
Ir-Vax by ImmunoRestoration for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval
Ir-Vax is under clinical development by ImmunoRestoration and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Positive...
Ir-Vax by ImmunoRestoration for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Ir-Vax is under clinical development by ImmunoRestoration and currently in Phase I for Human Epidermal Growth Factor Receptor 2 Negative...